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ABSTRACT
MepR is a multidrug binding transcription regulator
that represses expression of the Staphylococcus
aureus multidrug efflux pump gene, mepA, as well
as its own gene. MepR is induced by multiple catio-
nic toxins, which are also substrates of MepA.
In order to understand the gene regulatory and
drug-binding mechanisms of MepR, we carried out
biochemical, in vivo and structural studies. The
2.40A ˚ resolution structure of drug-free MepR
reveals the most open MarR family protein confor-
mation to date, which will require a huge conforma-
tional change to bind cognate DNA. DNA-binding
data show that MepR uses a dual regulatory binding
mode as the repressor binds the mepA operator as
a dimer of dimers, but binds the mepR operator as
a single dimer. Alignment of the six half sites reveals
the consensus MepR binding site, 5’-GTTAGAT-3’.
‘Drug’ binding studies show that MepR binds to
ethidium and DAPI with comparable affinities
(Kd=2.6 and 4.5kM, respectively), but with signifi-
cantly lower affinity to the larger rhodamine 6G
(Kd=62.6kM). Mapping clinically relevant or in vitro
selected MepR mutants onto the MepR structure
suggests that their defective repressor phenotypes
are due to structural and allosteric defects.
INTRODUCTION
Staphylococcus aureus is a leading cause of multidrug
resistant infections, ranging from skin and soft tissue
infections to endocarditis, in hospitals as well as commu-
nity settings (1). Multidrug-resistant organisms employ a
variety of mechanisms to negate the toxic eﬀects of vari-
ous antimicrobials that include alteration of the target
or drug and preclusion of their intracellular accumulation
by active extrusion by polyspeciﬁc or low speciﬁcity eﬄux
transporters (2–4). Multidrug resistance eﬄux pumps
(mdr pumps) were originally identiﬁed in human cancer
cells that showed resistance to ﬂuoroquinolones, but are
present in all living organisms (5). These promiscuous
membrane-embedded transporters bind to structurally
and chemically dissimilar compounds and pump them
out of the cell using the proton motive force or ATP
hydrolysis (2). The activity of mdr eﬄux pumps promotes
the persistence of pathogens in sanitized environments and
allows them to acquire high level target-based resistance.
Eﬄux pumps are categorized into ﬁve diﬀerent families:
the major facilitator super (MFS) family, ATP-binding
cassette (ABC) transporters, small multidrug resistance
(SMR) transporters, multidrug and toxic compound
extrusion (MATE) family and resistance-nodulation-cell
division (RND) family (6,7). Amongst the various mdr
pumps identiﬁed in S. aureus, most belong to the MFS
or SMR family (5) but recent genetic and microbiological
studies on multidrug resistant S. aureus strains identiﬁed
the ﬁrst MATE family multidrug transporter, MepA (8,9).
MepA confers resistance to a wide range of compounds,
which include various dyes, biocides, ﬂuoroquinolones
and the glycylcycline, tigecycline (9,10). Genetic analysis
of the open reading frame of mepA reveals that the gene is
part of the three-gene cluster, mepRAB, which encodes,
MepR, a MarR family transcription regulator, MepA,
the MATE-family transporter with 12 transmembrane
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belongs to the uncharacterized but highly conserved
COG4815 family (Figure 1) (9). Analogous to other
described multidrug eﬄux systems MepR negatively reg-
ulates mepR and mepA (and possibly mepB) expression by
binding to promoter sequences upstream of the mepR and
mepA transcription start sites, respectively (Figure 1).
Repression is relieved by MepR binding to one of a mul-
titude of structurally and chemically diﬀerent monovalent
and bivalent cationic, lipophilic drugs (11). The signiﬁ-
cance of MepR-dependent mepA regulation and its role
in multidrug resistance is underscored by the ﬁnding of
multidrug-resistant clinical isolates of S. aureus, which
contain mutations in the mepR gene that result in defective
repressor phenotypes (8,12).
MepR is a 139-residue protein that belongs to the MarR
family of transcription regulators. Members of the MarR
family have been implicated in the regulation of a variety
of bacterial adaptive responses including those to oxida-
tive stress and attack by toxins and biocides (13). MarR
family proteins also regulate genes that are responsible for
catabolism of aromatic compounds and encode virulence
determinants (13,14). Analogous to other MarR family
proteins, MepR represses transcription from the mepA
and mepR promoters by binding to sequences overlapping
the –35 and –10 hexamers (11). MepR is induced by bind-
ing to most, but not all, MepA substrates (11). Hence,
MepR is a cytosolic multidrug sensor and participates in
the defence against toxic compounds by regulating the
expression of mepA. The DNA-binding site of MepR is
characterized by the presence of pseudo palindromes as
well as a signature GTTAG motif (11). Though both the
mepA and mepR promoters have binding sites for MepR,
they diﬀer in location, complexity and multiplicity. The
mepA promoter binding site spans a 44 base pair segment
that consists of two inverted repeats, one overlapping the
–35 element and the other extending into the –10 hexamer.
There are two GTTAG motifs. By contrast, the MepR-
binding site in the mepR promoter is characterized by a
single inverted repeat and one GTTAG motif. This site
includes the –10 hexamer and the transcription start site
of the gene. An initial biochemical analyses of each
MepR–promoter interaction revealed that MepR binds
to the mepA promoter sequence with greater aﬃnity
than to the mepR promoter and MepR-mediated
repression of the mepA promoter is complete relative to
the leaky repression of the mepR promoter (11). Upon
exposure to MepA substrates, MepR readily dissociates
from the mepA promoter, whereas little to no eﬀect was
observed on mepR promoter (11). Amongst the various
MepA substrates assayed, chlorhexidine, cetrimide,
dequalinium, benzalkonium chloride (BAC), pentamidine
and tetraphenylphosphonium bromide (TPP
+) relieve
MepR-dependent repression of mepA (11).
At present, the structural basis of multidrug binding
and recognition by MarR family members is quite limited
with only the structures of Escherichia coli MarR and
Methanobacterium MarR bound to salicylate determined
(15,16). It is worth mentioning that the cationic nature
of MepR inducers is unusual amongst the MarR family
of transcription regulators, as most of the functionally
characterized proteins that belong to this family bind
to neutral or anionic lipophilic compounds (15,17–20).
Regardless, much of our structural understanding of
multidrug binding and recognition has been derived
from multiple structures of the ligand bound gene regula-
tors, QacR, and TtgR, which belong to TetR family of
regulators, and BmrR, a MerR family member (21–23).
The structures of QacR and TtgR in complex with various
inducers revealed the presence of a voluminous, multifa-
ceted drug-binding pocket that accommodates diverse
drugs by their interaction with diﬀerent parts of the multi-
drug-binding pocket. The inner face of the drug-binding
site is typically lined with an array of aromatic and hydro-
phobic residues, which are involved in van der Waals,
stacking and cation–  interactions with the lipophilic
compounds as well as charge neutralizing acidic or basic
residues that can interact with the respective positive or
negative charge of the drug (21–23). It remains to be seen
whether MepR utilizes similar mechanisms to interact
with its cationic ligands, speciﬁcally the use of multiple
negative charges within the cationic drug-binding pocket
and the presence of multiple minipockets similar to QacR
or a single, more rigidly ﬁxed pocket as observed in BmrR
(21,22,24). Moreover, the impressive drug-binding proﬁle
of MepR should shed light into a unique model system as
well as the multidrug-binding properties of all MarR
family proteins.
In order to understand more fully the biochemical and
structural mechanisms of multidrug and DNA binding by
MepR, we determined the crystal structure of drug-free
MepR at 2.4A ˚ resolution and carried out drug and
DNA-binding studies. The structure also provided insight
into the loss of repressor function of MepR mutants that
have been identiﬁed in clinical isolates and in vitro
selection.
EXPERIMENTAL PROCEDURE
Bacterial strains, plasmids, media andreagents
The strains and plasmids used in this study are listed
in Table 1. LB broth was used for routine cell growth
and protein overexpression. The growth media was
obtained from DIFCO, whereas the tryptic soy broth
and brain heart infusion were from BD Biosciences.
mepR mepA
 MATE – family multidrug
transporter
mepB
Protein of
unknown function
(–) (–)
MarR family
transcription
regulator
Figure 1. Genetic organization of the mepR, mepA and mepB genes.
The open rectangular boxes represent the region encoding the respec-
tive genes, which are labelled below, and the shaded rectangles indicate
the relevant promoter sequences, which encompass MepR-binding sites.
The inverted repeats within the MepR-binding sites are indicated by
head-to-head inverted arrows. The thick bent arrows above the rectan-
gles denote the transcription start sites and the thin curved arrows with
the negative signs below, indicate the promoters negatively regulated by
MepR. The mepB gene does have a MepR-binding site.
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assays was purchased from Operon Biotechnologies.
All other reagents were obtained from Sigma-Aldrich
Chemical Co.
Protein overexpression andpurification
The construction of the MepR overexpression plasmid has
been described elsewhere (11). Brieﬂy, the mepR gene was
cloned under the control of the T7 promoter with a hexa-
histidine tag encoded at its 30-end. Protein overexpression
was achieved using the strain BL21 DE3 star. An over-
night culture grown in 200ml LB broth containing 40mg/
ml ampicillin was transferred into 9l of LB broth supple-
mented with 40 mg/ml ampicillin and allowed to grow
at 378C until the OD600 reached 0.5–0.6. MepR overex-
pression was induced by the addition of 1mM IPTG and
incubation at 378C for 3h. Cells were harvested by cen-
trifugation and stored at –808C. The frozen cells were
thawed and resuspended in 50ml of Buﬀer A (20mM
Tris–HCl pH 7.5, 200mM NaCl, 2.5% glycerol and
1mM TCEP) with one protease cocktail inhibitor pellet
and 200mg of DNase I. Cells were lysed by a microﬂuidi-
zer M-110L (Microﬂuidics) followed by centrifugation
at 15000rpm for 30min to remove the cell debris.
The cleared lysate was applied to Ni-NTA resin pre-
equilibrated with Buﬀer A. After washing with 25
column volumes of Buﬀer A, MepR was eluted with a
0–300mM imidazole gradient. MepR elutes at  100mM
imidazole. Further puriﬁcation and buﬀer exchange with
Buﬀer A was achieved by gel-ﬁltration chromatography
using a Superdex-200 column. Protein was puriﬁed to
>95% homogeneity and was concentrated to  30mg/ml
using a YM-10 (10kDa cutoﬀ) centricon. The protein
concentration was estimated by a Bradford assay (25)
using bovine serum albumin as the standard and con-
ﬁrmed by mass spectrometry and amino acid analysis.
Selenomethionine-substituted MepR (SeMet MepR) was
overexpressed using the methionine inhibitory pathway
(26) and puriﬁed as described for native MepR.
Crystallization and datacollection
MepR was crystallized at room temperature using the
hanging drop vapor diﬀusion method by mixing equal
volumes of puriﬁed MepR and the reservoir solution,
which contained 14–16% PEG 4000, 0.2M MgSO4,
10% glycerol and additive NDSB-256. Both native and
SeMet-MepR crystals grown in this condition belong to
the space group P212121 with cell dimensions: a=32.2A ˚ ,
b=96.6A ˚ , c=110.3A ˚ . Native and SeMet crystals were
ﬂash frozen in liquid nitrogen using 20% glycerol as the
cryo-protectant. X-ray intensity data were collected at the
Advanced Light Source (ALS) Beamline 8.3.1at 100K.
Intensity data processing and scaling were carried out
using MOSFLM and SCALA (27,28). Native intensity
data were collected to 2.40A ˚ resolution and multiple
wavelength anomalous dispersion (MAD) data were col-
lected to 2.60A ˚ . Selected intensity data statistics are given
in Table 2.
Structure determination and refinement
Ten selenium sites, indicative of two MepR subunits
(12 selenium sites in totu) per asymmetric unit, were
located and reﬁned with SOLVE using MAD data to
2.6A ˚ resolution. The resulting ﬁgure of merit was 0.52.
Solvent ﬂattening in RESOLVE (29,30) resulted in a
much improved electron density map. Model building of
the MepR dimer was done with ‘O’ (31) and Coot (32) and
all reﬁnement was performed using CNS (33). After suc-
cessive rounds of positional and B-factor reﬁnement and
model rebuilding, the initial model contained residues
4–82 and 88–139 of each subunit. This structure was
reﬁned against the native data to 2.40A ˚ resolution. The
ﬁnal model contains residues 3–84 and 87–139 of subunit
A and residues 4–81 and 89–139 of subunit B, 196 water
molecules and ﬁve sulphate ions. Due to poor electron
density, the side chains of residues 82, 83, 87 and 88 of
subunit A were truncated to alanine. The reﬁned model
has a ﬁnal Rfree of 0.288 and Rwork of 0.239 for all data in
the resolution range of 50.0–2.40A ˚ . Selected data collec-
tion, phasing and reﬁnement statistics are given in Table 2.
All ﬁgures were generated using Pymol (34). The coordi-
nates and structure factors have been deposited in the
RCSB with PDB accession code 3ECO.
Fluorescence polarization assay
Fluorescence polarization-based MepR-ligand binding
experiments were performed with a Panvera Beacon
Fluorescence polarization system (Invitrogen) utilizing
the intrinsic ﬂuorescence of ﬂuorescein labelled DNA or
MepR inducers, ethidium (Et), rhodamine 6G (R6G) and
40,6-diamidino-2-phenylindole (DAPI). The polarization
(P) of the labelled DNA or drugs increases as a function
of protein binding and equilibrium dissociation constants
are determined from plots of millipolarization (P   10
–3)
against protein concentration. For MepR-DNA-binding
studies, 1 nM 50-ﬂuoresceinated oligodeoxynucleotide of
various lengths in 1ml binding buﬀer (20mM Tris–HCl
Table 1. Strains and plasmids used for MepR functional analyses
Strain or plasmid Relevant characteristic(s)
a Source or
reference
S. aureus strains
SA-K2916 SH1000 mepR::lacZ (11)
SA-K2916-R SA-K2916/pK434 (11)
SA-K2916-R (Q18P) SA-K2916/pK580 (8)
SA-K2916-R (G97E) SA-K2916/pK582 (8)
SA-K2916-R (G97W) SA-K2916/pK491 This study
SA-K2916-R (A103V) SA-K2916/pK519 (46)
Plasmids
pALC2073 S. aureus vector containing
a tetracycline-inducible
promoter controlling
expression of cloned
genes; Cm
r
(35)
pK434 pALC2073 mepR wt (9)
pK491 pALC2073 mepR (G97W) This study
pK519 pALC2073 mepR (A103V) (46)
pK580 pALC2073 mepR (Q18P) (8)
pK582 pALC2073 mepR (G97E) (8)
aCm
r, chloramphenicol resistance selection.
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against increasing concentrations of puriﬁed MepR and
the resulting change in polarization measured. Samples
were excited at 490nm and emission measured at
530nm. The MepR-drug-binding studies were carried
out in a drug-binding buﬀer composed of 20mM Tris–
HCl pH 7.5, 200mM NaCl and 2.5% glycerol. The exci-
tation wavelengths were 490, 490 and 330nm, respectively
for R6G, Et and DAPI and the emission measured
at wavelengths of 560, 620 and 560nm, respectively.
All data were plotted using Kaleidagraph and the resulting
plots were ﬁtted with the equation P={(Pbound Pfree)
[protein]/(KD+[protein])}+Pfree, where P is the polar-
ization measured at a given protein concentration, Pfree
is the initial polarization of the free ligand, Pbound is the
maximum polarization of speciﬁcally bound ligand and
[protein] is the protein concentration. Non-linear least
squares analysis was used to determine Pbound, and Kd.
The binding constant reported is the average value from
three independent experimental measurements.
b-galactosidase assay
An in vivo transcription assay system was employed to
determine the functional integrity of various MepR
mutant proteins that had been identiﬁed in previous stu-
dies (8,12). The construction of the tetracycline-inducible
MepR overexpression plasmid pALC2073 has been
described elsewhere (35). These pALC2073-based con-
structs were transduced into SA-K2916, which contains
a chromosomal mepR::lacZ transcriptional fusion (11).
Using a b-galactosidase assay the eﬀect of induction of
plasmid-based mepR expression on chromosomal mepR
regulated b-galactosidase expression could be determined.
Test strains were grown overnight in Trypticase Soy
broth, washed with phosphate-buﬀered saline (pH 7.0),
and diluted 1:200 in 100ml prewarmed Brain–Heart
Infusion broth, with or without 50ng/ml tetracycline,
and grown at 378C with agitation. b-galactosidase activity
was measured employing 4-methylumbelliferyl-b-D-galac-
topyranoside (MUG) as a substrate. Brieﬂy, 0.5ml culture
aliquots were taken at intervals during growth for mea-
surement of OD600. Cells in a second 0.5ml aliquot were
harvested by centrifugation and the pellets snap frozen at
–808C whilst awaiting assay. To assay for b-galactosidase
activity, cells were thawed, resuspended in 0.5ml ABT
(100mM NaCl, 60mM K2HPO4,4 0m MK H 2PO4, 0.1%
Triton X-100), and incubated at 378C for 15min. Fifty
microlitres MUG (4mg/ml stock) were then added and
the mixture incubated at room temperature for an addi-
tional hour. The reaction was stopped by the addition of
0.5ml 0.4M Na2CO3. Samples were serially diluted in a
1:1 (v:v) mixture of ABT and Na2CO3 in 96-well polysty-
rene microtiter plates. A range of concentrations of MUG
was used to generate a standard curve and b-galactosidase
Table 2. Selected crystallographic data and statistics
SeMet Native
Data collection and phasing
Wavelength ( ) 0.9797 0.9798 1.02 1.116
Resolution (A ˚ ) 50.0–2.60
Rsym
a 0.092 (0.22)
b 0.06 (0.19) 0.07 (0.21) 0.046 (0.14)
I/s(I) 12.3 (4.1) 16.1 (5.5) 14.5 (4.7) 25.6 (8.4)
Total reﬂections (#) 43794 44245 43757 54688
Unique reﬂections (#) 12590 12712 12621 14174
Completeness (%) 100 (100) 99.9 (100) 100 (100) 100 (99.8)
Selenium sites (#) 10
Overall ﬁgure of merit
c 0.52
Native MepR reﬁnement statistics
Resolution range (A ˚ ) 50.0–2.40
Rwork/Rfree(%)
d 23.9/28.8
Atoms (#)
Protein 2128
Sulphate ions 5
Solvent 196
B factors (A ˚ 2) 38.2
Rmsd
Bond lengths (A ˚ ) 0.006
Bond angles (8) 1.007
B for bonded main-chain
atoms (A ˚ 2)
1.397
Ramachandran analysis
Most favoured (%) 95.9
Add. allowed (%) 4.1
Gen. allowed (%) 0.0
Disallowed (%) 0.0
aRsym=
PP
|Ihkl Ihkl(j)|/
P
Ihkl, where Ihkl(j) is the observed intensity and Ihkl is the ﬁnal average intensity value.
bValues in parentheses are for the highest resolution shell.
cFigure of Merit=<|RP( )e
i /RP( )|>, where   is the phase and P( ) is the phase probability distribution.
dRwork=R||Fobs| |Fcalc||/R|Fobs| and Rfree=R||Fobs| |Fcalc||/R|Fobs|; where all reﬂections belong to a test set of 5% randomly selected reﬂections.
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cleaved per min per OD600) was determined by ﬂuores-
cence using a Bio-Tek FLx800 plate reader (Bio-Tek
Instruments, Inc., Winooski, VT, USA). Cumulative chro-
mosomal mepR expression over the course of 10h exper-
iment was determined by integrating the area beneath
expression curves using software from the SigmaPlot
11.0 suite (Systat Software, Inc., Point Richmond,
CA, USA).
Size exclusion/gel-filtration chromatography
Size exclusion/gel-ﬁltration chromatography was used
to determine the oligomerization states of apo MepR
and two MepR–DNA complexes. A Superdex 200 26/60
column (Amersham Pharmacia Biotech) with a mobile
phase containing 20mM Tris–HCl pH 7.5, 200mM
NaCl and 2.5% glycerol was used in the gel-ﬁltration
experiments. Blue dextran (Sigma) was used to determine
the void volume of the column. The size exclusion column
was calibrated using RNase A (Mr 13 700kDa), carbonic
anhydrase (Mr 29 000kDa), bovine serum albumin (Mr 66
000kDa) and alcohol dehydrogenase (Mr 150000kDa).
The KAverage (Kav) was calculated using the equation
Kav=(VE–VO)/(VT–VO), where VT, VE and VO are the
total column volume, elution volume and void volume of
the column, respectively. A standard plot was obtained by
graphing the logarithm of the molecular weight (Mr)
against the Kav (Kaleidagraph). The Kav of each marker
as well as the experimental samples were the average value
of two or more experiments.
RESULTS AND DISCUSSION
Structure ofMepR
The drug-free or apo structure of MepR was determined
to 2.4A ˚ resolution by multiwavelength anomalous disper-
sion (MAD) methods using selenomethionine-substituted
MepR. The asymmetric unit contains one MepR dimer.
The ﬁnal reﬁned models exhibited excellent stereochemis-
try with 100% of the observed residues in the most
favored (95.9%) and additionally allowed (4.1%) regions
of the Ramachandran plot (Table 2).
MepR is predominantly a helical with six a helices and a
two-stranded antiparallel b hairpin and an overall topol-
ogy of a1 (residues 5–26) -a2 (residues 31–42) -a3 (residues
50–57) -a4 (residues 61–74) -b1 (residues 77–81) - W1 (the
tip of the Wing, residues 82–84)-b2 (residues 88–93) -a5
(residues 95–118) -a6 (residues 121–139) (Figure 2A and
C). Each subunit is composed of two functional domains:
a dimerization domain that includes helices a1, a5 and a6,
and a DNA-binding domain with a winged helix-turn-
helix (wHTH) motif (a3,a4,b1,W1, b2) in the middle of
the polypeptide chain (Figure 2B). The DNA-binding
domain is connected to the dimerization domain by helices
a2 and a5. Unlike most MarR family members, the apo
MepR structure lacks a third b strand typically located
between a2 and a3. Residues located at the tip of the
wing, between b1 and b2, are either missing completely
or have had their side chains truncated to alanines.
The disorder in this region is likely due to the inherent
ﬂexibility of the wing in the absence of DNA as observed
in other MarR family members such as OhrR (36,37).
Superimposition of the individual subunits of the MepR
dimer revealed a remarkable degree of ﬂexibility with a
root mean square deviation (r.m.s.d.) of 2.2A ˚ for 127
corresponding Ca atoms (Figure 3A). This degree of con-
formational asymmetry of subunits within the same dimer
has not been observed previously in the unliganded struc-
tures of any other MarR family members. Given the vari-
ation amongst the MarR family members in the lengths of
their cognate DNA-binding sites and their spacer regions
as well as the size, charge and hydrophobicity of their
diﬀerent inducers, an inherently ﬂexible molecule is clearly
required for the transition between diﬀerent functional
states (14).
The dimerinterface of MepR
The MepR dimer has the typical ‘safety triangle’ shape of
the MarR family with its dimerization domain in the apex
of the triangle, whilst the two-winged helix-turn-helix
(wHTH) motifs are located at the base (Figure 2B). In
this arrangement, a wide cleft is created between the two
DNA-binding domains. The dimer interface is formed by
the burial of hydrophobic residues located on the internal
faces of helices a1, a5 and a6 of one subunit along with
similar residues from their dyadic mates (a10, a50 and a60,
where 0 denotes the second subunit). Speciﬁcally, Tyr5,
Leu8, Phe9, Ile12 and Met16 in the N-terminal half of
a1 interact with Met1110, Leu1150 and Leu1190 of a50 as
well as Met1270, Leu1310 and Leu1350 of a60. The same
interactions are made by their dyadic mates. These hydro-
phobic interactions are masked from the solvent by polar
interactions between Asn130 and Glu1230, Gln1180 and
Lys133, and Gln126 and Gln1260. The extensive interac-
tion between the subunits leads to the burial of 3475 A ˚ 2
accessible surface area (ASA) in the dimer interface.
Although the sequence identity of these residues varies
amongst the MarR family members, the hydrophobic
nature of the residues is highly conserved (Figure 2C).
Conformational incompatibility for DNA binding
The wHTH motif of MepR is composed of helices a3 and
a4 (the recognition helix) and the following antiparallel b
hairpin formed by b1, b2 and a four-residue connecting
loop, i.e. the wing (W1) (38,39) (Figure 2B and C). Most
of the intradomain contacts of the wHTH motif are lim-
ited to the hydrophobic interactions between the family
wide, highly conserved non-polar residues located on
the internal face of helices a2, a3, a4, b1, b2 and the
N-terminal half of helix a5. With few exceptions, the rec-
ognition helix makes base-speciﬁc contacts in the major
groove, whereas the wing interacts speciﬁcally with the
bases in the adjacent minor groove or with the phosphate
backbone in a non-speciﬁc fashion (38,39). To date only
one crystal structure of a MarR family member–DNA
complex has been reported, that of B. subtilis OhrR
bound to the ohrA operator sequence (36). That structure
revealed that the duplex DNA runs through a cleft
between the DNA-binding domains with the 2-fold related
recognition helices of the OhrR dimer interacting with
Nucleic Acids Research,2009, Vol.37, No. 4 1215pseudo palindromic sequences of consecutive major
grooves. The wings are extended on either side of the rec-
ognition helices making speciﬁc and non-speciﬁc contacts
with the bases in the minor groove (36). A third DNA-
binding element, the helix-helix (HH) motif, formed by
helices a1 and a2, interacts with the DNA backbone in
the spacer region that connects the pseudo palindromes
(36). As observed for most apo MarR family member
structures, drug-free MepR is not conﬁgured for DNA
binding. First, the distance between the midpoints of
the recognition helices [R69 (Ca) – R690 (Ca)] is  43A ˚
(Figure 3B) which is incompatible with binding consecu-
tive major grooves of B-DNA ( 34A ˚ ). Second, the super-
imposition of MepR and DNA-bound OhrR reveals the
W1
B
C
C
N A Dimer interface
wHTH motif
Figure 2. Structure of MepR. (A) Ribbon diagram of the MepR subunit. The secondary structural elements are labelled and rainbow colored from
red (N-terminus) to blue (C-terminus). The N- and C-termini are indicated as N and C, respectively. With the exception of the loops between b1 and
b2, all loops are colored grey. (B) Ribbon diagram of the MepR dimer. The secondary structure elements of one subunit is color coded as in
Figure 2A. The dyadic mate is colored magenta. The dimerization interface and the winged helix-turn-helix motif (wHTH) are labelled. (C) Primary
sequence alignment of MepR with other structurally characterized MarR family members [MepR, B. subtilis OhrR (OhrR-B), X. campestris OhrR
(OhrR-X), E. coli MarR, P. aeruginosa MexR and Methanobacterium MarR, MTH313]. The multiple sequence alignment was made with ClustalW
(45). The secondary structure elements of MepR are indicated above the alignment, a helices as rectangles and b strands as arrows, and colored as
in Figure 2A. Identical residues are colored red and the chemically similar residues are blue. The conserved hydrophobic residues that are involved
in dimerization are highlighted in shaded boxes. The magenta asterisks (
 ) indicate the positions of MepR mutations that had been identiﬁed from
clinically isolated or in vitro selected multidrug-resistant strains of S. aureus.
1216 Nucleic Acids Research, 2009, Vol. 37,No. 4outward displacement of all DNA-binding elements of
MepR such that in addition to the increased distance
between the recognition helices, the distance between the
HH motifs of MepR is 7A ˚ longer than those of DNA-
bound OhrR (Figure 3B). Third, the corresponding
winged helices of MepR and DNA-bound OhrR, although
equally distanced in the two dimers, take quite diﬀerent
orientations whereby the wings of MepR are nearly per-
pendicular to those of OhrR (Figure 3B).
MepR is captured in an extended form incompatible
with B-DNA binding. Indeed, comparison with all
other structurally characterized MarR family members
reveals that MepR takes the most extended structure
(Supplementary Table 1). Only reduced apo Bs OhrR
(35A ˚ ) and oxidized Xc OhrR (35A ˚ ) show signiﬁcant
widening between their recognition helices (Supple-
mentary Table 1). By contrast, the midpoints of the
recognition helices of most MarR family members range
from 23 to 32A ˚ . Of these, only apo HucR and one of the
four diﬀerent dimer conformers of MexR (MexR-CD),
which shows a midpoint distance of 29A ˚ , could be mod-
elled successfully onto B-DNA. Interestingly, we were also
able to place the recently determined MarRM-salicylate
complex, which has a center-to-center distance between
recognition helices of 30A ˚ , onto a B-DNA site (data not
shown) (40,41). The 29–30A ˚ distances between the mid-
points of the recognition helices are close to that measured
between the recognition helices of Bs OhrR bound to
DNA (31A ˚ ). By contrast to MepR, some MarR family
members, including apo MarRM and one dimer of apo
MexR (MexR AB) display quite short center-to-center
distances of 23 and 24A ˚ , respectively. Thus, MarR
family members display a huge range of motion allow-
ing the DNA-binding domains to span at least 20A ˚ .
wHTH motif
A N
C
C
B
43 Å
31 Å
wHTH motif
180˚
N
C
N C
N
N
C
C
Figure 3. Conformational plasticity of MepR. (A) Superimposition of the two subunits of the MepR dimer with subunit A colored light pink and
subunit B, red. Subunits are depicted as ribbons and the location of the N- and C-termini are labelled N and C, respectively. (B) Superimposition of
the MepR dimer (light pink) and DNA-bound OhrR dimer (cyan), using the entire polypeptide chain. The wHTH motifs of MepR and DNA-bound
OhrR are colored red and yellow, respectively. The midpoints of the recognition helices of MepR and OhrR are shown as spheres and their
intersubunit distances provided above by the arrows. (C) Superimposition of the subunits of selected MarR family members (MepR, apoOhrR,
Xc OhrROxi, DNA-bound Bs OhrR, E. coli MarR, Methanobacterium MarR, and MexR). The wHTH motifs of each protein are colored light pink
and labelled. The N- and C-termini of MepR are colored black and cyan, respectively, and labelled, whereas the N- and C-termini of all the other
proteins are colored green and red and labelled N (green) and C (red), respectively. On the right, the overlays are rotated 1808 along the y-axis.
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tor for DNA-binding as the proper conformation and ori-
entation of DNA-binding elements are necessary as well.
However, it would appear that the center-to-center dis-
tance of the recognition helices of MarR family members
must be  30A ˚ for DNA binding. Clearly, the observed
conformation of apo MepR is not suited for high aﬃnity
DNA binding and requires signiﬁcant changes to eﬀect
such binding to the mepA and mepR operator sites.
Conformational flexibility ofMepR and its structural
homologues
The superimposition of the subunits of MepR revealed
a remarkable degree of conformational plasticity with an
r.m.s.d. of 2.2A ˚ . Inspection of the overlay shows that most
of the structural diﬀerences lie in the dimerization domain
of each subunit (Figure 3A and B). Such structural asym-
metry within a dimer is unusual amongst the structurally
characterized MarR family members, i.e. their dyadic sub-
units typically take very similar conformations. By con-
trast and as seen with other MarR family members, the
DNA-binding domains of MepR (residues 50–93) and
other MarR family members exhibit a high degree of struc-
tural similarity with r.m.s.d. ranging from 0.9 to 1.0A ˚
(Figure 3C). Given the 2.2A ˚ diﬀerence between the two
subunits of MepR, it might be expected that the dimeriza-
tion domains of MepR and other MarR family members
display signiﬁcant diﬀerences in the relative positions of
their a1, a5 and a6 helices. Indeed, the largest positional
diﬀerences reside in the N-terminus of a1, the C-terminal
half of a5, and the entirety of helix a6 (Figure 3C).
Conformational plasticity of these helices has been
observed previously in the structures of OhrR, MexR
and EmrR (37,40,42) and we would suggest that the intrin-
sic ﬂexibility of these structural elements provides the
impetus for the structural transitions that occur between
the diﬀerent functional states of each protein viz., the apo,
DNA bound and induced states. Consistent with this sup-
position, the structures of OhrR in its diﬀerent functional
states, i.e. reduced, DNA-free, DNA-bound and oxidized
(induced), reveal that key structural and functional
rearrangements are found in the loop between a1 and
a2, helix a5, the loop between a5 and a6, and a6. The
end result is a rigid body movement of the DNA-binding
domains (36,37).
DNA binding by MepR
MepR autoregulates its own expression and mepA expres-
sion independently by binding to similar but not identical
gene-speciﬁc operator sequences (11). Biochemical analy-
sis of the sequences upstream of mepR and the sequences
in the intergenic region of mepR-mepA has identiﬁed two
MepR binding sites (11). In that study, a diﬀerential
response to drugs on these promoters was noted as
MepR readily dissociated from the mepA promoter upon
the addition of drugs but far less so from the mepR oper-
ator (11). Footprinting studies of the mepA and mepR
promoters with MepR identiﬁed a 43bp binding site in
the mepA promoter and 26bp site in the mepR promoter
(11). Analysis of these binding sites revealed pseudo
palindromic sequences that overlapped crucial promoter
elements as well as a GTTAG signature motif. The mepA
promoter possesses two of these motifs whilst the mepR
promoter has only one (11). Based on these observations,
it was proposed that a diﬀerential aﬃnity for mepA
and mepR operator sequences could be due to the plurality
of these MepR-binding elements in the former promoter
region.
In order to determine the minimal sequence required
for MepR binding, ﬂuorescent polarization-based DNA-
binding assays were carried out with various lengths of
oligodeoxy-nucleotides, which encompassed the proposed
MepR-binding sites in the mepA and mepR promoters.
Results from the titration experiments indicate that
MepR binds to a 44bp duplex covering the ‘full’ MepR
footprint of the mepA promoter with a dissociation con-
stant (Kd) of 6.3 nM (Figure 4A). Interestingly, truncation
of downstream sequences had little eﬀect on MepR bind-
ing whereby the dissociation constant for a 26bp oligo-
deoxynucleotide, which does not include 18bp from
the 30-end of the 44bp site, was only  2.4-fold lower
(Kd=15.3 nM) than that of the complete mepA site
(Figure 4B). Removal of four additional base pairs further
impairs MepR binding to the mepA site another 3.3-fold
(Kd=46.4 nM) but binding remains relatively tight with
only a cumulative  7-fold loss in aﬃnity as compared
to the 44bp site (Figure 4C and F). By contrast, deletion
of eight base pairs from the 50-end of the 44mer causes
a greater than 30-fold reduction (Kd=186.9 nM) in the
aﬃnity of MepR for the mepA-binding site (Figure 4D).
DNA-binding experiments with the 26bp MepR-binding
site from mepR promoter also showed high-aﬃnity bind-
ing (Kd=24.3 nM) that essentially matches the aﬃnity of
the tested 26-bp fragment from the mepA promoter and is
only  4-fold lower than that of the full 44bp mepA site
(Figure 4B and E). Thus, the previously observed diﬀer-
ential response to drugs, i.e. the slower release of MepR
from mepR operator site, does not appear to correlate
well with MepR–DNA-binding aﬃnity and suggests that
MepR binds to mepA and mepR-binding sites somewhat
diﬀerently, whereby subsequent drug binding to MepR
when bound to mepR promoter is less eﬀective in induc-
tion than drug binding to MepR bound to mepA-binding
site.
The diﬀerent lengths of the MepR-binding sites in the
mepA and mepR promoters suggest that MepR binds to
these sequences with diﬀerent stoichiometries. To deter-
mine the number of MepR dimers that bind each site,
size exclusion chromatography was utilized. The elution
volumes of MepR, MepR complexed with the ‘half site’
(27bp DNA) and ‘full site’ (44bp DNA) sequences from
the mepA promoter were determined and the molecular
weights for each species calculated (Figure 5A, Table 3).
As expected, puriﬁed MepR eluted at a volume, which
corresponds closely to the calculated molecular weight of
a dimer (37.6 versus 33.7kDa). The elution volume for
MepR bound to the half site indicates a molecular mass
of 62.8kDa, which is near but noticeably larger than the
calculated 50.3kDa molecular weight of a MepR dimer
bound to the 27bp half site (Figure 5A). The discrepancy
between the calculated and experimental values is
1218 Nucleic Acids Research, 2009, Vol. 37,No. 4the likely result of the non-spherical shape of the MepR–
DNA complex. Gel-ﬁltration experiments with MepR
complexed to the full site give a molecular weight of
147.2kDa. This value would suggest strongly that
more than one MepR dimer bind to the 44bp promoter
sequences (calculated Mr=60.8kDa) (Table 3). Given
the diﬀerences in DNA and protein shapes, a thin rigid
rod of DNA bound to a triangle-shaped protein very
likely runs anomalously through the column. Consistent
with this, the elution volume of the 44bp duplex DNA
comprising the mepA full site alone indicates a molecular
weight of  75kDa, which is signiﬁcantly greater than its
calculated molecular weight of  29kDa. In light of this
information, the added values of the calculated molecular
weight of the anomalously migrating individual compo-
nents, 75 and 37kDa for the 44bp duplex and MepR
dimer, respectively, correlates well with the experimen-
tally determined molecular weight (147kDa) of two
MepR dimers complexed to the 44bp site (2 37kDa+
75kDa=149kDa) (Table 3).
The gel-ﬁltration elution properties of MepR and DNA
prompted us to carry out a ﬂuorescent polarization-based
stoichiometry assay in which the DNA-binding site
was added in 20-fold molar excess of its Kd and titrated
5′ TTATAGTTAGATATCTAATTGTTAGTAAGCTAATTATTGGAAAA -3′
3′ AAT ATCAATCTATAGATTAACAATCATT CGATTAATAACCT T TT -5′
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Figure 4. Binding isotherms of MepR and selected ligands. (A through D) MepR-binding isotherms to various lengths of cognate DNA from the
mepA promoter. (A) MepR binding to a 44-bp site encompassing the entire mepA promoter DNase I footprint. (B) MepR binding to a 26-bp site of
the mepA promoter that has been truncated from the 30-end. (C) MepR binding to a 22-bp site of the mepA promoter that has been truncated from
the 30-end. (D) MepR binding to a 31-bp site of the mepA promoter that has been truncated from the 50-end. (E) MepR-binding isotherms to a 26-bp
DNA binding site from the mepR promoter. (F) Nucleotide sequence of the mepA promoter. The –10 and –35 elements of the promoter are shown in
bold and labelled and the transcription start site (TSS) is indicated as a bent arrow. The pseudo-inverted repeats of the promoter are shown by
horizontal arrows and the signature GTTAG motifs are underlined. The boundaries of the 22, 26 and 31-bp sequences used in the binding studies
are indicated by blue, red and purple rectangles, respectively. G–I, MepR-binding isotherms for three ‘drugs’. (G) The MepR-Et-binding isotherm.
(H) The MepR-DAPI-binding isotherm. (I) The MepR-R6G-binding isotherm. The change in polarization, shown in red circles and indicated
in millipolarization units (mP), was plotted against the MepR dimer concentration indicated inside each plot. The binding constants are shown
in each plot. The chemical structure of each drug is shown below the respective binding curve.
Nucleic Acids Research,2009, Vol.37, No. 4 1219Apo MepR
MepR-half site
   complex
MepR-full 
site complex
A
B
C
D
5′ TTATAGTTAGATATCTAATTGTTAGTAAGCTAATTATTGGAAAA 3′
3′ AATATCAATCTATAGATTAACAATCATTCGATTAATAACCTTTT  5′
−35 −10 TSS
5′ TATTTAGTTAGACATCTAACGAATGG 3′
3′ ATAAATCAATCTGTAGATTGCT TACC 5′
TSS
mepA half site 1   5′- G T T A G A T - 3′
mepA half site 2   5′- A T T A G A T - 3′
mepA half site 3   5′- G T T A G T A - 3′
mepA half site 4   5′- A T T A G C T - 3′
mepR half site 5   5′- G T T A G A C - 3′
mepR half site 6   5′- G T T A G A T - 3′
Consensus MepR 
  half site
  5′- G T T A G A T - 3′
44 bp 
oligoduplex
Log molecular weight
K
a
v
A
D
E
B
m
i
l
l
i
p
o
l
a
r
i
z
a
t
i
o
n
 
(
m
P
)
F
C
m
i
l
l
i
p
o
l
a
r
i
z
a
t
i
o
n
 
(
m
P
)
Primary site Secondary site
Figure 5. Stoichiometry of MepR binding to the conserved pseudo palindromes located in the mepA and mepR promoters. (A) Size exclusion
chromatography of MepR and MepR–DNA complexes. The linear ﬁt of the elution values of four standard proteins [(A), ribonuclease A (Mr,
13.7kDa); (B), carbonic anhydrase (Mr, 29kDa); (C), bovine serum albumin (Mr, 66kDa); (D), alcohol dehydrogenase (Mr, 150kDa)] is shown as a
red line. The Kav of MepR and MepR bound to the 44 and 27bp high-aﬃnity binding sites of the mepA promoter was plotted on the graph (solid
blue rectangles) and labelled. (B and C) Fluorescence polarization-based determination of MepR–mepA-binding stoichiometry. (B) Binding to the
44bp mepA operator site. (C) Binding to the 26bp mepA operator site. The linear ﬁt for the high aﬃnity (speciﬁc) and low aﬃnity (non-speciﬁc)
binding are color coded in red and blue, respectively. The inﬂection points that denote the breaking point of high and low-aﬃnity binding are
indicated by black arrows. (D) The sequence of the MepR-binding sites on the mepA promoter. The 44-bp sequence comprising the MepR footprint
of the mepA promoter is shown with the –10 and –35 hexamers of the promoter underlined and labelled. The primary binding site of MepR is
indicated by solid inverted arrows, whereas the secondary site is shown as broken inverted arrows. The transcription start site (TSS) is marked by a
bent arrow. (E) The sequence of the MepR-binding sites on the mepR promoter. The pseudo palindrome is shown as solid inverted arrows and the
transcription start is indicated by the bent arrow. (F) Alignment of the heptanucleotide sequences of the MepR binding half sites of the mepA and
mepR promoters. The half sites from the MepR primary (MepR sites 1 and 2) and secondary sites (sites 3 and 4) of the mepA operator and from the
MepR-binding site of the mepR promoter (sites 5 and 6) are aligned from 50!30 direction and the consensus sequence derived from the sequence
similarity amongst the six sequences is shown at the bottom of the alignment.
Table 3. Data from size exclusion/gel ﬁltration experiments for MepR and MepR bound to various lengths of cognate DNA
MepR/MepR–DNA
complexes
Oligomerization state Predicted molecular
weight (kDa)
Experimentally determined
molecular weight (kDa)
Apo MepR Dimer 33.7 37.6
Tetramer 67.4
MepR-27bp Dimer—27bp 50.3 63.1
Dimer of dimers—27bp 84.0
MepR-44bp Dimer—44bp 60.8 147.2
Dimer of dimers—44bp 94.5
44bp oligoduplex – 27.0 75.0
1220 Nucleic Acids Research, 2009, Vol. 37,No. 4with protein. Polarization was then measured at each pro-
tein dimer titration point and the MepR concentration at
the inﬂection point of the resulting curve used to deduce
the stoichiometry. The results from the 44bp duplexes
showed that the inﬂection point, i.e. the point at which
all high-aﬃnity (speciﬁc) sites are bound, occurs at 400nM
MepR dimer in a binding experiment that contains
200nM dsDNA, thus demonstrating that two MepR
dimers bind speciﬁcally to the full site (Figure 5B).
Analogous experiments with the 27bp duplex showed
that MepR binds to the smaller site as a dimer as the
inﬂection point occurs at 200nM MepR dimer
(Figure 5C). The diﬀerent stoichiometries of MepR for
the full and half sites of cognate DNA indicate that
MepR employs diﬀerent mechanisms in its regulation of
mepA and mepR expression.
The mechanism with which MepR binds the mepA oper-
ator will require the crystal structures of appropriate
repressor–DNA complexes. However, insight into the
mepA-binding mode of MepR can be gained by reference
to the crystal structure of B. subtilis OhrR–ohrA complex,
in which the ohrA-binding site contains the 12bp inverted
repeat (50-ATTGTA TACAAT-30) that is ﬂanked on
either side by A-T rich sequences (36). The OhrR recog-
nition helices make symmetric contacts with the palindro-
mic sequences whilst the wings make speciﬁc as well as
non-speciﬁc contacts with the upstream and downstream
A-T rich minor grooves. Inspection of mepA promoter
sequences reveals a similar arrangement of binding ele-
ments and leads to the proposal that the nearly perfect
repeat, 5’-GTTAGAT ATCTAAT-3’, which spans from
–35 to –22 of the mepA promoter and contains the GTT
AG signature motif, is the ‘speciﬁcity’ element for the rec-
ognition helices, whilst the ﬂanking A-T rich region
provides the interacting surface for the wings of the
wHTH motif (Figure 5D). In addition, a second putative
MepR-binding site, 5’-GTTAGTA AGCTAAT-3’, that
exhibits strong sequence conservation to the other
MepR-binding element is found between –20 and –7 and
overlaps the –10 hexamer of the mepA promoter
(Figure 5D).
On the basis of these observations and our binding data,
we propose that the palindrome, which overlaps the –35
hexamer, is the primary, higher aﬃnity MepR-binding site
and the pseudopalindrome that encompasses the –10 hex-
amer is a lower aﬃnity second site. Consistent with this,
MepR binds with high aﬃnity to the 26bp fragment that
contains the entire primary site as a single dimer, whereas
two dimers interact with the full site, which is comprised
of both the primary and the secondary binding site
(Figures 4A,B, 5A and B) (Table. 3). Removal of down-
stream sequences, which keeps the primary palindrome
intact, has little eﬀect on the binding aﬃnity (Figure 4B,
C and F). However, destruction of the left half of primary
site, as seen in the mepA 31bp fragment, lowers the bind-
ing aﬃnity by >30-fold (Figure 4D and F) indicating that
the secondary site is signiﬁcantly weaker than the pro-
posed primary site. Similar to the mepA sites, the MepR-
binding site in the mepR promoter is a nearly perfect
palindrome, 5’-GTTAGAC ATCTAAC-30, that includes
the transcription start site and is located between –4 and
+10 sequence with a laterally located upstream A-T rich
sequence (Figures 4E and 5E). Thus, alignment of the
sequences of the six heptanucleotide half sites of the
mepA and mepR promoters reveals the consensus half
site sequence 5’-GTTAGAT-30 (Figure 5F).
Given the nature of the speciﬁcity elements, location,
and the multiplicity of binding site, the tighter repression
from the mepA promoter by MepR can be explained by
the presence of both high- and low-aﬃnity binding sites
that overlaps crucial promoter elements. Thus, when
MepR is bound to the mepA promoter, perhaps coopera-
tively as a dimer of dimers, the –10 and –35 hexamer bind-
ing elements of RNA polymerase (RNAP) are occluded,
thereby mediating eﬀective repression. By contrast, the
weaker interactions between MepR and its binding site
in the mepR promoter as well as the locus of the MepR
binding site results in the blockage of only the –
10 box from RNAP. RNAP binding at the –35 element
would result in transcription from the mepR promoter by
dissociation of MepR as part of its normal on and oﬀ
DNA-binding equilibrium (11). Although still unclear,
the poorer ability of drugs to induce MepR from the
mepR promoter suggests the intriguing possibility that
the diﬀerences between the mepR and consensus
sequences, for example substitution of the central TpA
step by CpA, alter the MepR conformation such that
when bound to mepR, drug binding by the repressor is
diminished as suggested by earlier drug induced DNA
‘knock oﬀ’ experiments (11), or conformational changes
in MepR induced by weaker inducer binding is insuﬃcient
to promote complete induction. Moreover, cooperative
binding by MepR dimers to the mepA operator could
also play a role in the rapid induction of this promoter
by drug. Additional structural and biochemical studies
should clarify these observations.
Analyses ofMepR mutants
Several MepR mutations have been found in multidrug-
resistant S. aureus clinical isolates and by in vitro selection.
One mutation, which results in the replacement of MepR
residue A103 by valine (A103V), was obtained from
a multidrug-resistant strain found in blood samples of
a patient (12), whereas three others, G97E, G97W and
Q18P, were derived from bacteria that were exposed to a
variety of drugs in vitro in either a single step or gradient
exposure (8). The functional integrity of these mutants
was tested by their ability to repress the expression of
b-galactosidase from a mepR-lacZ fusion. The expression
of b-galactosidase from a mepR-lacZ fusion was measured
before and after the induction of MepR expression from a
plasmid carrying the mepR gene under a tetracycline indu-
cible promoter. Upon induction, the wild-type MepR
represses gene expression from the mepR promoter by
greater than 5-fold, whereas the four mutant proteins dis-
played a 90% or greater reduction in their repressor func-
tion (Figure 6A).
In order to deduce a possible structural explanation for
the observed phenotypes of these mutants, each was
mapped onto the MepR structure (Figure 6B). With the
exception of residue G97, the side chains of residues Q18
Nucleic Acids Research,2009, Vol.37, No. 4 1221and A103 are surface exposed and located on the external
face of helices a1 and a5, respectively (Figure 6B). By
contrast, the ‘side chain’ of G97 points towards the hydro-
phobic core of the wHTH motif and is positioned in the
vicinity of multiple hydrophobic residues (L37, Y41, L76,
I77, L93, I98, L100 and V101) from a2, a4, b1, b2 and a5.
This glycine is highly conserved amongst the members of
MarR family (Figure 2C). Model building reveals that
introduction of the bulky indole side chain of tryptophan
at position 97 would result in steric clash with the side
chains of residue L76, I77 and L93 as well as the main
chain of I77. Substitution of G97 by a glutamate would
place the carboxylate side chain in a hydrophobic envir-
onment, which is thermodynamically unfavorable and
would likely disrupt the hydrophobic core that is required
to maintain the structural integrity of wHTH motif.
Interestingly, the analogous G104D mutation in E. coli
MarR displayed a transdominant negative phenotype
with respect to its repressor function and had reduced
solubility, properties consistent with the compromise of
the hydrophobic core (43). When the G97E and G97W
mutant proteins were overexpressed, more than 95% of
each protein ended in the ‘insoluble’ fraction indicating
these substitutions disrupt the native MepR structure
and its thermodynamic stability (Supplementary Data
Figure 1).
The functional defect that arises from the Q18P substi-
tution is likely tied to its structural eﬀects. Proline strongly
disfavors the a helical conformation and when centrally
located in a helix, almost always kinks that structure.
Glutamine 18 is indeed located in the middle of helix a1
and its substitution by proline and any subsequent helix
distortion or breaking could aﬀect dimerization by alter-
ing the position of the N-terminus of a1 or DNA binding
by altering the location of the C-terminal half of a1
or both (Figure 6B). In addition, this change might
impair DNA binding as the analogous position in Bs
OhrR, residue K27, is part of the HH motif and engages
in DNA phosphate backbone contacts (36). Thus,
the Q18P substitution could disrupt DNA binding in mul-
tiple ways and result in defective repression by MepR.
Interestingly, the proline substitution at Q18 is well
tolerated, as the overexpression and solubility of this
protein are comparable to that of wild-type MepR
(Supplementary Data Figure 1).
Perhaps the most intriguing defective repressor is the
A103V-substituted MepR as the alanine to valine muta-
tion is a relatively conservative substitution and the side
chain is solvent exposed, thus ruling out any obvious steric
clash eﬀects (Figure 6B). Regardless, the eﬀect of substi-
tuting alanine to valine is possibly conformational simply
because alanine prefers the a helical conformation, whilst
valine prefers the b-strand structure. The A!V change
could weaken the a-helical propensity of a5 as a whole
or more likely cause a local conformational deformation
that locks in or favors the induced state. Any role of the
A!V substitution on solubility and stability of the pro-
tein was ruled out, as most of the overexpressed A103V
protein remains in the soluble fraction of the cell lysate
(Supplementary Data Figure 1). Although a seemingly
harmless substitution, the structures of oxidized OhrR
and DNA-bound OhrR underscore the critical importance
of the conformational plasticity of helix a5, as this helix
must be reformed upon the reduction of organic hydro-
peroxide oxidised OhrR in order to transmit this informa-
tion to the wHTH motifs to eﬀect cognate DNA binding
and repression (36,37). Thus, a seemingly ‘innocuous’
change could have a profound eﬀect on structure and
function.
MepR–‘drug’ interactions
MepR is induced by binding to a variety of lipophilic
monovalent and bivalent cationic biocides, drugs, dyes,
antiseptics and disinfectants (11). The binding aﬃnities
of MepR for several inducers namely, Et, DAPI, and
R6G were determined using the intrinsic ﬂuorescence
polarization of each compound. MepR binds to Et with
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Figure 6. Functional characterization of clinically isolated or in vitro
selected MepR mutants. (A) Histograms of MUG units obtained from
b-galactosidase assays for various MepR mutations. Measurements
were made in the presence (+) and absence (–) of tetracycline, the
addition of which causes MepR production. (B) Structural mapping
of MepR mutations. The side chains of the mutated residues are
shown as red sticks and labelled. One subunit is colored pink and
the other blue. The secondary structure elements of one subunit are
labelled.
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DAPI, a bivalent cationic compound, with a nearly equal
equilibrium dissociation constant of 4.5mM (Figure 4G
and H). By contrast, MepR binds R6G with relatively
poor aﬃnity (Kd value of 62.6mM) (Figure 4I). Thus, it
would appear that the larger R6G (accessible surface
area=754.5A ˚ 2) does not ﬁt the multidrug-binding
pocket of MepR as well as the smaller aromatic monova-
lent cation, Et (ASA=508.7A ˚ 2) or even the bivalent dia-
midine DAPI (ASA=486.6A ˚ 2).
Our current knowledge of inducer binding by MarR
family members is mostly derived from the structures
of MarR from E. coli and Methanobacterium bound
to salicylate, DNA-bound and organic hydroperoxide
(OHP) oxidised OhrR, the latter of which is the induced
state, and MexR bound to the eﬀector peptide ArmR
(15,16,37,40,44). The crystal structure of oxidised OhrR
displays drastic conformational changes upon OHP-oxi-
dation that involve the reactive OHP sensor cysteine and
aromatic and aliphatic residues from a1, a2, a5 and a6
(37). In OhrR, the only MarR family member for which
the apo, DNA-bound and induced structures are available
presently, the cascade of structural changes that occurs
upon OHP induction originate in the dimerization inter-
face and the structural components, which connect the
dimerization and DNA-binding domains. These latter
movements in turn lead to the movement of wHTH
motifs as rigid bodies to positions incompatible with
high-aﬃnity DNA binding. Intriguingly, the salicylate
bound structures of MarR from E. coli and Methanobac-
terium reveal distinct drug-binding modes and stoichiome-
tries (15,16). Amongst the four diﬀerent salicylate-binding
sites, ‘site 1’ of the Methanobacterium MarR was pro-
posed to be the physiologically relevant drug binding
site, mostly due to the major structural rearrangements
that occur as a result of salicylate binding to this particu-
lar site. The salicylate in site 1 interacts primarily by
hydrophobic and charged residues from helix a1 of one
subunit and a2, a3 and a5 of the second subunit.
The recently determined structure of the MexR dimer
bound to one molecule of the peptide inducer, ArmR,
also reveals a similarly located but slightly larger inducer
binding pocket situated between the dimerization and
DNA-binding domains of MexR (44). The ArmR-binding
site in MexR is composed of four hydrophobic pockets
with symmetrical contributions from both subunits.
MexR interacts with the C-terminal tail of ArmR, which
is rich in aromatic residues largely by using hydrophobic
and polar residues from helix a1, a2 and a5 of both sub-
units (44). Inspection of the corresponding region of
MepR reveals that this area too is rich in aromatic and
hydrophobic residues (L24, F27, I29, L37, L40, L100,
F104 and F109) that are surrounded by a small number
of acidic and polar residues (D21, E32 and H36). These
acidic residues could serve as charge complements to the
binding of lipophilic, cationic drugs. Thus, it is possible
that the multidrug-binding pocket of MepR is located sim-
ilarly to the OHP, salicylate and ArmR-binding sites of
OhrR, MarRM and MexR and that this is the canonical
ligand binding site of the MarR family. Germane struc-
tural studies are underway to test this conjecture.
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